InSilico Medicine Cayman TopCo
Research InSilico Medicine Cayman TopCo (3696.HK) on Bullrun: market cap HKD 22.63B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3696.HK
- ExchangeHK
- CountryHong Kong
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 22.63B
- Financial periodFY2025
- RevenueUSD 56.24M
- Revenue growth-34.5%
- Net income-USD 352.32M
- Free cash flow-USD 79.74M
- Gross margin81.5%
Valuation Snapshot
latest market cap is HKD 22.63B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 56.24M | -USD 352.32M | -USD 79.74M | 81.5% | -4.48 | USD 393.34M | USD 5.96M | USD 452.03M |
| FY2024 | USD 85.83M | -USD 17.10M | -USD 58.33M | 90.4% | -0.03 | USD 125.94M | USD 2.56M | -USD 663.92M |
| FY2023 | USD 51.18M | -USD 211.64M | -USD 32.55M | 75.4% | -0.38 | USD 177.18M | USD 2.19M | -USD 650.16M |
| FY2022 | USD 30.15M | -USD 221.83M | -USD 58.74M | 63.4% | -0.4 | USD 207.88M | USD 3.22M | -USD 449.54M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 22.63B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is InSilico Medicine Cayman TopCo's market cap?
InSilico Medicine Cayman TopCo's market capitalization is HKD 22.63B.
What does InSilico Medicine Cayman TopCo do?
InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas.